APP and Alzheimer disease: The initial design of the attempted iAβ depletion therapy in the treatment of symptomatic AD (discussed in Section 17 and Section 18 above), when the AβPP-independent iAβ generation pathway is operational, was to reduce the levels of iAβ to those below the T1 threshold [4,8].